Phio Pharmaceuticals Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Phio Pharmaceuticals de 221.7% y 256.9% respectivamente, mientras que el BPA crecerá en un 195.2% al año.

Información clave

221.7%

Tasa de crecimiento de los beneficios

195.2%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	28.4%
Tasa de crecimiento de los ingresos	256.9%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	14 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Phio Pharmaceuticals appoints interim executive chairman

Sep 29

Phio Pharmaceuticals GAAP EPS of -$0.19 beats by $0.12

Aug 11

Is Phio Pharmaceuticals (NASDAQ:PHIO) In A Good Position To Deliver On Growth Plans?

Apr 11

Phio soars 22% on positive in vivo data on combination PD-1 and TIGIT therapy in cancer

Nov 09

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:PHIO - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	75	48	N/A	N/A	1
12/31/2024	N/A	-10	N/A	N/A	1
9/30/2024	N/A	-7	-8	-8	N/A
6/30/2024	N/A	-9	-9	-9	N/A
3/31/2024	N/A	-9	-10	-10	N/A
12/31/2023	N/A	-11	-11	-11	N/A
9/30/2023	N/A	-12	-11	-11	N/A
6/30/2023	N/A	-12	-12	-12	N/A
3/31/2023	N/A	-12	-11	-11	N/A
12/31/2022	N/A	-11	-12	-12	N/A
9/30/2022	N/A	-12	-12	-12	N/A
6/30/2022	N/A	-12	-11	-11	N/A
3/31/2022	N/A	-13	-12	-12	N/A
12/31/2021	N/A	-13	-12	-12	N/A
9/30/2021	N/A	-12	-12	-12	N/A
6/30/2021	N/A	-11	-11	-11	N/A
3/31/2021	N/A	-10	-10	-10	N/A
12/31/2020	N/A	-9	-9	-9	N/A
9/30/2020	N/A	-9	-9	-9	N/A
6/30/2020	N/A	-9	-9	-9	N/A
3/31/2020	N/A	-9	-9	-9	N/A
12/31/2019	0	-9	-9	-9	N/A
9/30/2019	0	-8	-8	-8	N/A
6/30/2019	0	-7	-8	-8	N/A
3/31/2019	0	-7	-8	-8	N/A
12/31/2018	0	-7	-8	-8	N/A
9/30/2018	0	-8	-8	-8	N/A
6/30/2018	0	-9	N/A	-8	N/A
3/31/2018	0	-9	N/A	-9	N/A
12/31/2017	0	-12	N/A	-10	N/A
9/30/2017	N/A	-15	N/A	-9	N/A
6/30/2017	N/A	-15	N/A	-8	N/A
3/31/2017	0	-14	N/A	-8	N/A
12/31/2016	0	-11	N/A	-8	N/A
9/30/2016	0	-9	N/A	-8	N/A
6/30/2016	0	-10	N/A	-8	N/A
3/31/2016	0	-10	N/A	-8	N/A
12/31/2015	0	-10	N/A	-7	N/A
9/30/2015	0	-11	N/A	-7	N/A
6/30/2015	0	-11	N/A	-7	N/A
3/31/2015	0	-12	N/A	-7	N/A
12/31/2014	0	-13	N/A	-8	N/A
9/30/2014	0	-14	N/A	-8	N/A
6/30/2014	0	-14	N/A	-8	N/A
3/31/2014	0	-16	N/A	-8	N/A
12/31/2013	0	-30	N/A	-6	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que PHIO sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.6%).

Beneficios vs. Mercado: Se prevé que PHIO sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que PHIO sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (256.9% al año) de PHIO crezcan más rápidamente que los del mercado US (9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (256.9% al año) de PHIO crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de PHIO se prevé que sea elevada dentro de 3 años.

Phio Pharmaceuticals Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 33% to US$36.00

Forecast to breakeven in 2025

Price target decreased to US$6.00

Price target decreased to US$6.00

Recent updates

Price target decreased by 33% to US$36.00

Forecast to breakeven in 2025

Phio Pharmaceuticals Corp. Announces Robert M. Infarinato as New Chief Financial Officer

Phio Pharmaceuticals Corp Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study

Phio Pharmaceuticals Corp. Presents New Data About Its Lead Clinical Product Candidate, PH-762

Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)

Phio Pharmaceuticals Corp. Presents Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies

Phio Pharmaceuticals Corp. Announces Addition of Clinical Trial Sites At Banner Md Anderson Cancer Center, the George Washington University, and Integrity Research

Phio Pharmaceuticals Corp. Announces Patent Granted by Uspto, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin Disorders

Phio Pharmaceuticals Receives Non-Compliance Notice from Nasdaq

Phio Pharmaceuticals Corp. Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas

Phio Pharmaceuticals Corp. Announces the Presentation of New Preclinical Data At the 38Th Annual Meeting of the Society for Immunotherapy of Cancer

Phio Pharmaceuticals Corp. Presents New Data for Targeting of BRD4 with its INTASYL Compound PH-894

Phio Pharmaceuticals Corp. Announces Dosing of First Patient in Collaborative Clinical Trial with Agonox, Inc. and Providence Cancer Institute

Phio Pharmaceuticals Corp., Annual General Meeting, Jul 20, 2023

Phio Pharmaceuticals Corp. announced that it expects to receive $3.000002 million in funding

Phio Pharmaceuticals Corp Presents Preclinical Study Showing INTASYL Treatment of NK Cells More than Doubles Ability to Kill Tumor Cells

Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas

Phio Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

Phio Pharmaceuticals Corp. Announces Positive DMC Recommendation and Continued Enrollment of Advanced Melanoma Study Without Modification

Phio Pharmaceuticals Announces New Clinical Program to Study PH-762 for the Treatment of Cutaneous Squamous Cell Carcinoma

Phio Pharmaceuticals Announces New Clinical Program to Study PH-762 for the Treatment of Cutaneous Squamous Cell Carcinoma

Phio Pharmaceuticals Corp. Announces Study Results at the 37th Annual Meeting of the Society for Immunotherapy of Cancer on November 10th and 11th

Phio Pharmaceuticals Corp. Announces Study Results at the 37th Annual Meeting of the Society for Immunotherapy of Cancer on November 10th and 11th

Phio Pharmaceuticals Corp. Announces Board Appointments

Phio Pharmaceuticals appoints interim executive chairman

Phio Pharmaceuticals Corp. Announces Preclinical Data Demonstrating PH-762 Enhances Persistence of T Cells for Tumor Cell Killing as Presented by Helmholtz Munich at the 9th Immunotherapy of Cancer Conference

Phio Pharmaceuticals Discloses Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

Phio Pharmaceuticals GAAP EPS of -$0.19 beats by $0.12

Phio Pharmaceuticals Corp., Annual General Meeting, Aug 09, 2022

Phio Pharmaceuticals Corp. Presents New Data Demonstrating PH-894 Enhances Activity of Her2-Car T Cells At ASGCT 2022

Phio Pharmaceuticals Corp. Announces Management Changes

Phio Pharmaceuticals Corp. Announces the Appointment of Patricia A. Bradford to Its Board of Directors

Price target decreased to US$6.00

Is Phio Pharmaceuticals (NASDAQ:PHIO) In A Good Position To Deliver On Growth Plans?

Phio Pharmaceuticals Corp. Presents Positive New Data on PH-894 Demonstrating Antitumor Efficacy in Model of PD-1 Refractory Disease at AACR Annual Meeting 2022

Phio Pharmaceuticals Corp. Initiates In Vivo Studies of INTASYL Based Antivirals Against SARS-CoV-2

Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial for PH-762 to Treat Melanoma

Price target decreased to US$6.00

Phio Pharmaceuticals Presents Data at ESMO 2021 Demonstrating Persistent Anti-Tumor Immunity with INTASYL Dual-Targeting PD-1 and BRD4

Phio Pharmaceuticals Presents New in Vivo Data At the 2021 Asco Annual Meeting Showing Dual-Targeting Intasyl Offers Increased Efficacy and Safety Potential over Other Therapeutic Approaches

Phio Pharmaceuticals Presents Positive In Vivo Data at ASGCT Showing PH-762 Significantly Enhanced Antitumor Efficacy of HER2-Targeted CAR-T Cells

Phio Pharmaceuticals and AgonOx Inc. Announces Collaboration on Clinical Development of Novel T Cell-Based Cancer Immunotherapies

Phio Pharmaceuticals Corp. has completed a Follow-on Equity Offering in the amount of $7.684001 million.

Phio Pharmaceuticals Corp. announced that it has received $14.001908 million in funding

Phio Pharmaceuticals Corp. announced that it expects to receive $14.002049 million in funding

Phio Pharmaceuticals Corp. Announces Positive in Vivo Data on Combination PD-1 and TIGIT Checkpoint Blockade with INTASYL in a Single Therapeutic for Cancer Treatment

Phio soars 22% on positive in vivo data on combination PD-1 and TIGIT therapy in cancer

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento